Selank — compound monograph
Synthetic tuftsin analogue heptapeptide. Approved. The Institute assesses 1 outcome for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Selank
- Compound class
- Synthetic tuftsin analogue heptapeptide
- Assessment series
- Neuroactive peptides
- Synonyms and codes
- Thr-Lys-Pro-Arg-Pro-Gly-Pro · tuftsin analogue · heptapeptide Selank
- Route as evaluated
- Intranasal in the approved presentation
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 129954-34-3
- Molecular formula
- C33H57N11O9
- Average mass
- 751.88
- Monoisotopic mass
- 751.43
- ATC classification
- not assigned
§1.3Sequence and structural notes
A heptapeptide comprising the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension, following the same design logic as Semax. Registered in the Russian Federation as an anxiolytic.
§1.4Assessment status
The Institute assesses Selank across 1 indication and grades the strongest of them at low certainty. Holds a marketing authorisation for at least one indication in at least one jurisdiction.
Table 1. Assessed outcomes for Selank, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Cognitive performance and neuroprotection | Russian clinical studies report anxiolytic effect comparable to benzodiazepines without sedation or withdrawal | Very low | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.